Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Angiotensin II for distributive shock
ACTRN12621000281897Phase 2Completed
- Sponsor
- Austin Health
- Start
- Apr 2021
- Modality
- Recombinant Proteins and Enzymes, Peptides
- Countries
- 1
01
Overview
Phase 2, open-label trial of Angiotensin II in Vasoplegia (2 arms), sponsored by Austin Health. Primary endpoint: Peak serum creatinine. Started Apr 2021; status: completed.
02
Drugs
Angiotensin II
03
Conditions
Vasoplegia
Beyond the preview
Go deeper on ACTRN12621000281897.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12621000281897.